Anna Mullard

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory et al. · The Lancet Oncology · 2023 · 81 citations · Full text

Medicine, Oncology, Pharmacology +11

The detection of germline and somatic <i>BRCA1/2</i> genetic variants through parallel testing of patients with high‐grade serous ovarian cancer: a national retrospective audit

Bethan Frugtniet, Sue Morgan, Alexandra Murray et al. · BJOG An International Journal of Obstetrics & Gynaecology · 2021 · 19 citations · Full text

Medicine, Genetics, Oncology +17

Checklists for Complications During Systemic Cancer Treatment Shared by Patients, Friends, and Health Care Professionals: Prospective Interventional Cohort Study

Helen V Jones, Harry Smith, Tim Cooksley et al. · JMIR mhealth and uhealth · 2020 · 17 citations · Full text

Medicine, Oncology, Medical Oncology +13

Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up

Alison Finall, Gareth Reynold Davies, Trevor Jones et al. · Journal of Clinical Pathology · 2022 · 15 citations

Medicine, Oncology, Pathology +17

Intractable Malignant Ascites: An Alternative Management Option

Anna Mullard, Jill M. Bishop, Mahdi Jibani · Journal of Palliative Medicine · 2011 · 10 citations

Medicine, Oncology, Medical Oncology +6